Bristol Puts U.S. Consumer Business On The Selling Block
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to contact potential buyers for the OTC business "over the coming weeks." Novartis and GSK are understood to be interested in Bristol's North American consumer business.
You may also be interested in...
Teva Loses Pravachol Exclusivity Period; Multiple Generics To Launch In 2006
FDA tells Teva that the 180-day exclusivity period for three pravastatin doses expired in February. As a result, as many as six companies – including Teva – could be in a position to launch generic Pravachol when Bristol’s composition of matter patent expires in April 2006. Teva plans to sue FDA to reinstate its first-to-file exclusivity period.
Teva Loses Pravachol Exclusivity Period; Multiple Generics To Launch In 2006
FDA tells Teva that the 180-day exclusivity period for three pravastatin doses expired in February. As a result, as many as six companies – including Teva – could be in a position to launch generic Pravachol when Bristol’s composition of matter patent expires in April 2006. Teva plans to sue FDA to reinstate its first-to-file exclusivity period.
Pravachol OTC Deal Reached Between Bayer, Bristol
Bristol will handle the regulatory filing of the switch NDA and advisory committee presentation for pravastatin 20 mg, while Bayer Consumer Care will handle OTC sales and marketing if FDA approves the cholesterol-lowering agent for nonprescription sale.